OBSV - ObsEva SA

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
12.52
-0.46 (-3.54%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close12.98
Open13.04
Bid12.39 x 3000
Ask12.52 x 800
Day's Range12.29 - 13.04
52 Week Range6.15 - 20.35
Volume48,371
Avg. Volume150,575
Market Cap568.174M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-2.21
Earnings DateAug 13, 2018 - Aug 17, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est31.00
Trade prices are not sourced from all markets
  • GlobeNewswire7 days ago

    ObsEva SA to Participate in Wedbush PacGrow Healthcare Conference August 14-15, 2018

    Geneva, Switzerland and Boston, MA- August 10, 2018- ObsEva SA, a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions ...

  • ObsEva SA (OBSV) Reports Q2 Loss, Misses Revenue Estimates
    Zacks8 days ago

    ObsEva SA (OBSV) Reports Q2 Loss, Misses Revenue Estimates

    ObsEva SA (OBSV) delivered earnings and revenue surprises of 9.26% and -100.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • ACCESSWIRE8 days ago

    ObsEva SA to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 8, 2018 / ObsEva SA (NASDAQ: OBSV ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 8:00 AM Eastern Time. To listen ...

  • GlobeNewswire9 days ago

    ObsEva Reports Second Quarter 2018 Financial Results and Provides Business Update

    Phase 2 b EDELWEISS clinical trial of linzagolix in endometriosis related pelvic pain achieved primary and secondary endpoints Chief Commercial Officer hired as nolasiban moves closer to commercialization ...

  • ObsEva SA (OBSV) Sees Hammer Chart Pattern: Time to Buy?
    Zacks14 days ago

    ObsEva SA (OBSV) Sees Hammer Chart Pattern: Time to Buy?

    ObsEva has been struggling lately, but the selling pressure may be coming to an end soon.

  • GlobeNewswire16 days ago

    ObsEva SA to Hold Second Quarter 2018 Financial Results and Business Update Call on August 8, 2018

    Geneva, Switzerland and Boston, MA - July 31, 2018 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics ...

  • GlobeNewswire17 days ago

    ObsEva SA to Hold Second Quarter 2018 Financial Results and Business Update Call on August 8, 2018

    Geneva, Switzerland and Boston, MA- July 31, 2018- ObsEva SA, a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions ...

  • GlobeNewswire23 days ago

    ObsEva Expands Executive Team Hiring a Chief Commercial Officer

    July 25, 2018 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman`s reproductive health and pregnancy, today announced the appointment of a Chief Commercial Officer, Wim Souverijns, who will be based at the Company headquarters in Geneva, Switzerland. Mr. Souverijns brings nearly 20 years of experience in the pharmaceutical industry and recently served as Corporate Vice President, Global Marketing, Hematology & Oncology within Celgene out of Summit, New Jersey.

  • GlobeNewswire23 days ago

    ObsEva Expands Executive Team Hiring a Chief Commercial Officer

    July 25, 2018 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, today announced the appointment of a Chief Commercial Officer, Wim Souverijns, who will be based at the Company headquarters in Geneva, Switzerland. Mr. Souverijns brings nearly 20 years of experience in the pharmaceutical industry and recently served as Corporate Vice President, Global Marketing, Hematology & Oncology within Celgene out of Summit, New Jersey.

  • GlobeNewswirelast month

    ObsEva SA to start trading today on the SIX Swiss Exchange

    July 13, 2018 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman`s reproductive health and pregnancy, announced that its shares will be listed and start trading today under the "International Reporting Standard" on SIX Swiss Exchange. The issued share capital comprises 45`381`252 registered shares with a nominal value of 1/13 of CHF 1 each.

  • GlobeNewswirelast month

    ObsEva SA to start trading today on the SIX Swiss Exchange

    July 13, 2018 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, announced that its shares will be listed and start trading today under the "International Reporting Standard" on SIX Swiss Exchange. The issued share capital comprises 45'381'252 registered shares with a nominal value of 1/13 of CHF 1 each.

  • Reuterslast month

    ObsEva plans Swiss listing; trading debut on July 13

    ObsEva, a Switzerland-based drug development company, said on Friday it plans a secondary listing on the SIX Swiss Exchange in Zurich and trading debut on July 13, as the firm seeks to gain more visibility among European investors. Geneva-based ObsEva, founded by gynaecologist and former Serono drug developer Ernest Loumaye, started trading on the Nasdaq in 2017 and has a market capitalisation of about $658 million. ObsEva, which will trade under the ticker symbol "OBSN.S", will not issue any new shares in connection with the Swiss listing.

  • GlobeNewswirelast month

    ObsEva SA Shares to Begin Trading on SIX Swiss Exchange

    ObsEva has a unique pipeline of novel and potential best-in class therapeutics to address serious conditions with a high unmet medical need affecting millions of women. Geneva, Switzerland and Boston, MA - July 6, 2018 - ObsEva SA (OBSV), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, today announced the listing of its shares on SIX Swiss Exchange with the publication of its listing prospectus.

  • GlobeNewswirelast month

    ObsEva SA Shares to Begin Trading on SIX Swiss Exchange

    ObsEva has a unique pipeline of novel and potential best-in class therapeutics to address serious conditions with a high unmet medical need affecting millions of women. Geneva, Switzerland and Boston, MA - July 6, 2018 - ObsEva SA (OBSV), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman`s reproductive health and pregnancy, today announced the listing of its shares on SIX Swiss Exchange with the publication of its listing prospectus.

  • GlobeNewswire2 months ago

    ObsEva Announces Pricing of Follow-on Public Offering

    June 20, 2018 - ObsEva SA (OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, announced today the pricing of an underwritten public offering of 4,750,000 common shares at a price of $15.39 per share, before underwriting discounts and commissions. In addition, ObsEva has granted the underwriters a 30-day option to purchase up to an additional 712,500 common shares at the public offering price, less the underwriting discounts and commissions. ObsEva anticipates the total gross proceeds from the offering (before deducting the underwriting discounts and commission and estimated offering expenses) will be $73.1 million, excluding any exercise of the underwriters' option to purchase additional shares.  ObsEva intends to use the net proceeds from the proposed offering primarily to continue the development of its three new chemical entities in its pipeline and invest in pre-commercial activates in support of its pipeline assets, and for working capital and other general corporate purposes.

  • GlobeNewswire2 months ago

    ObsEva Announces Pricing of Follow-on Public Offering

    June 20, 2018 - ObsEva SA (OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman`s reproductive health and pregnancy, announced today the pricing of an underwritten public offering of 4,750,000 common shares at a price of $15.39 per share, before underwriting discounts and commissions. In addition, ObsEva has granted the underwriters a 30-day option to purchase up to an additional 712,500 common shares at the public offering price, less the underwriting discounts and commissions. ObsEva anticipates the total gross proceeds from the offering (before deducting the underwriting discounts and commission and estimated offering expenses) will be $73.1 million, excluding any exercise of the underwriters` option to purchase additional shares.  ObsEva intends to use the net proceeds from the proposed offering primarily to continue the development of its three new chemical entities in its pipeline and invest in pre-commercial activates in support of its pipeline assets, and for working capital and other general corporate purposes.

  • GlobeNewswire2 months ago

    ObsEva Announces Launch of Proposed Follow-on Public Offering

    June 18, 2018 - ObsEva SA (OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman`s reproductive health and pregnancy, announced today the launch of a proposed underwritten public offering of 4,750,000 common shares. ObsEva intends to use the net proceeds from the proposed offering primarily to continue the development of its three new chemical entities in its pipeline and invest in pre-commercial activates in support of its pipeline assets, and for working capital and other general corporate purposes. J.P. Morgan Securities LLC, Credit Suisse Securities (USA) LLC and Jefferies LLC are acting as joint bookrunning managers.

  • GlobeNewswire2 months ago

    ObsEva Announces Launch of Proposed Follow-on Public Offering

    June 18, 2018 - ObsEva SA (OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, announced today the launch of a proposed underwritten public offering of 4,750,000 common shares. ObsEva intends to use the net proceeds from the proposed offering primarily to continue the development of its three new chemical entities in its pipeline and invest in pre-commercial activates in support of its pipeline assets, and for working capital and other general corporate purposes. J.P. Morgan Securities LLC, Credit Suisse Securities (USA) LLC and Jefferies LLC are acting as joint bookrunning managers.

  • GlobeNewswire2 months ago

    ObsEva SA Achieves Primary and Secondary Endpoints for EDELWEISS Phase 2b Clinical Trial of Linzagolix (OBE2109) in Women with Endometriosis

    Partial suppression of estradiol with moderate dose (75mg) of linzagolix demonstrated highly significant reduction of pain and improvement of patient well-being High dose (200mg) of linzagolix achieves ...

  • GlobeNewswire2 months ago

    ObsEva SA Achieves Primary and Secondary Endpoints for EDELWEISS Phase 2b Clinical Trial of Linzagolix (OBE2109) in Women with Endometriosis

    Partial suppression of estradiol with moderate dose of linzagolix demonstrated highly significant reduction of pain and improvement of patient well-being. High dose of linzagolix achieves full estradiol ...

  • GlobeNewswire2 months ago

    ObsEva SA to Hold Investor Call to Announce Topline Results of the EDELWEISS Phase 2b Clinical Trial of Linzagolix (OBE2109) in Women with Endometriosis-Associated Pain on Monday June 18, 2018

    Geneva, Switzerland and Boston, MA - June 15, 2018 - ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious ...

  • GlobeNewswire2 months ago

    ObsEva SA to Hold Investor Call to Announce Topline Results of the EDELWEISS Phase 2b Clinical Trial of Linzagolix (OBE2109) in Women with Endometriosis-Associated Pain on Monday June 18, 2018

    Geneva, Switzerland and Boston, MA- June 15, 2018- ObsEva SA, a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that ...

  • GlobeNewswire2 months ago

    ObsEva SA to Seek SIX Share Listing

    Geneva, Switzerland and Boston, MA -June 1, 2018 - ObsEva SA (OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, today announced its intention to request the listing of its shares on SIX Swiss Exchange under SIX's international reporting standard. "Last years listing on the NY based NASDAQ was a major step for the company as it provides access to capital to pursue the development of our rich, late-stage clinical, product portfolio, hence moving closer to address the needs of millions of women worldwide and continue to create value for our shareholders" said Ernest Loumaye, MD, PhD, OB/GYN, CEO and Co-Founder of ObsEva. "Today as a Swiss company, we are proud and thrilled to announce our intention to be listed on SIX.

  • GlobeNewswire2 months ago

    ObsEva SA to Seek SIX Share Listing

    Geneva, Switzerland and Boston, MA -June 1, 2018 - ObsEva SA (OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman`s reproductive health and pregnancy, today announced its intention to request the listing of its shares on SIX Swiss Exchange under SIX`s international reporting standard. "Last years listing on the NY based NASDAQ was a major step for the company as it provides access to capital to pursue the development of our rich, late-stage clinical, product portfolio, hence moving closer to address the needs of millions of women worldwide and continue to create value for our shareholders" said Ernest Loumaye, MD, PhD, OB/GYN, CEO and Co-Founder of ObsEva. "Today as a Swiss company, we are proud and thrilled to announce our intention to be listed on SIX.

  • GlobeNewswire3 months ago

    ObsEva SA to Participate in Jefferies Global Healthcare Conference June 5-8, 2018

    Geneva, Switzerland and Boston, MA -May 31, 2018 - ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious ...